News Releases
Aug 8, 2024
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update Read more
Aug 6, 2024
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors Read more
Jul 31, 2024
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer Read more
Jul 31, 2024
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer Read more
Jun 2, 2024
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer Read more
May 29, 2024
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference Read more
May 9, 2024
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update Read more
May 7, 2024
ALX Oncology Appoints Allison Dillon as Chief Business Officer Read more
Apr 30, 2024
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer Read more
Apr 24, 2024
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting Read more